Get the Stockscreener App
38.96
1.39%
-0.55
Pre-market:
38.81
-0.15
-0.39%
Protagonist Therapeutics Inc stock is traded at $38.96, with a volume of 455.14K.
It is down -1.39% in the last 24 hours and down -13.33% over the past month.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
See More
Previous Close:
$39.51
Open:
$39.2
24h Volume:
455.14K
Relative Volume:
0.72
Market Cap:
$2.32B
Revenue:
$45.48M
Net Income/Loss:
$169.95M
P/E Ratio:
-14.54
EPS:
-2.68
Net Cash Flow:
$230.85M
1W Performance:
-6.10%
1M Performance:
-13.33%
6M Performance:
+22.21%
1Y Performance:
+66.21%
1-Day Range:
$38.50
$39.68
1-Week Range:
$38.50
$41.27
52-Week Range:
$21.43
$48.89
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Name
Protagonist Therapeutics Inc
Sector
Industry
Phone
(510) 474-0170
Address
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
38.96 | 2.32B | 45.48M | 169.95M | 230.85M | 2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.76 | 105.27B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
712.40 | 78.29B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
626.31 | 37.79B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
237.97 | 30.69B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.95 | 27.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-06-24 | Initiated | Goldman | Neutral |
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Sep-24-24 | Initiated | TD Cowen | Buy |
| Sep-09-24 | Initiated | Truist | Buy |
| Oct-30-23 | Initiated | CapitalOne | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Aug-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Oct-12-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-11-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Sep-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-24-21 | Initiated | JMP Securities | Mkt Outperform |
| May-24-21 | Initiated | Northland Capital | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Dec-16-20 | Initiated | Piper Sandler | Overweight |
| Sep-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Initiated | Jefferies | Buy |
| May-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| May-09-19 | Upgrade | Stifel | Hold → Buy |
| Dec-06-18 | Initiated | Nomura | Buy |
| Jan-29-18 | Initiated | Stifel | Buy |
| Jul-21-17 | Initiated | BTIG Research | Buy |
View All
Protagonist Therapeutics Inc Stock (PTGX) Latest News
Where are the Opportunities in (PTGX) - Stock Traders Daily
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Franklin Resources Inc. - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Down 2.3%Here's Why - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Barclays PLC Boosts Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
HighTower Advisors LLC Trims Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Wellington Management Group LLP Makes New $1.35 Million Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025 - Batesville Daily Guard
Protagonist Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Teachers Retirement System of The State of Kentucky Purchases New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Y Intercept Hong Kong Ltd Trims Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
(PTGX) Trading Signals - Stock Traders Daily
Protagonist Therapeutics' SWOT analysis: stock poised for growth amid clinical trials - Investing.com
State Street Corp Boosts Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
XTX Topco Ltd Takes $666,000 Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Clear Street sets $63 target on Protagonist Therapeutics By Investing.com - Investing.com Canada
BNP Paribas Financial Markets Purchases 16,597 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
BTIG maintains shares target on Protagonist Therapeutics, cites trial By Investing.com - Investing.com Australia
HC Wainwright Reiterates "Buy" Rating for Protagonist Therapeutics (NASDAQ:PTGX) - MarketBeat
Fmr LLC Grows Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist's Rusfertide Shows Breakthrough Results in Phase 2 PV Study: 54% Hit Key Treatment Goals - StockTitan
The Goldman Sachs Group Begins Coverage on Protagonist Therapeutics (NASDAQ:PTGX) - MarketBeat
Weiss Asset Management LP Makes New $2.81 Million Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Point72 Asset Management L.P. Sells 694,862 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Now Covered by BMO Capital Markets - MarketBeat
BMO Capital Initiates Coverage of Protagonist Therapeutics (PTGX) with Outperform Recommendation - MSN
Protagonist Therapeutics price target raised to $58 from $43 at JMP Securities - Yahoo Finance
Charles Schwab Investment Management Inc. Buys 39,850 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
(PTGX) Technical Data - Stock Traders Daily
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by RTW Investments LP - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by HighVista Strategies LLC - MarketBeat
Walleye Capital LLC Makes New Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Public Sector Pension Investment Board Invests $5.62 Million in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Is Weakness In Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? - Yahoo Finance
Thrivent Financial for Lutherans Invests $2.08 Million in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Intech Investment Management LLC Invests $861,000 in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics chief development officer sells $5.6 million in stock By Investing.com - Investing.com Nigeria
Protagonist Therapeutics CEO sells $4.68 million in stock By Investing.com - Investing.com Nigeria
Protagonist Therapeutics' chief medical officer sells $1.41 million in stock By Investing.com - Investing.com South Africa
Swedbank AB Acquires New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics CEO sells $4.68 million in stock - Investing.com India
Protagonist Therapeutics' chief medical officer sells $1.41 million in stock - Investing.com India
Protagonist Therapeutics chief development officer sells $5.6 million in stock - Investing.com
Advantage Alpha Capital Partners LP Acquires Shares of 11,336 Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Rating of "Buy" by Brokerages - MarketBeat
Protagonist Therapeutics' SWOT analysis: stock poised for growth amid clinical milestones - Investing.com Nigeria
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Objective long/short (PTGX) Report - Stock Traders Daily
Algert Global LLC Sells 36,400 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Eagle Asset Management Inc. - MarketBeat
Protagonist Therapeutics Inc Stock (PTGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Protagonist Therapeutics Inc Stock (PTGX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MOLINA ARTURO MD | Chief Medical Officer |
Nov 26 '24 |
Option Exercise |
8.04 |
5,529 |
44,453 |
51,973 |
| MOLINA ARTURO MD | Chief Medical Officer |
Nov 27 '24 |
Sale |
44.70 |
26,000 |
1,162,280 |
46,444 |
| MOLINA ARTURO MD | Chief Medical Officer |
Nov 26 '24 |
Sale |
45.60 |
5,529 |
252,122 |
46,444 |
| Gupta Suneel | Chief Development Officer |
Nov 25 '24 |
Option Exercise |
7.75 |
175,000 |
1,356,000 |
359,611 |
| Gupta Suneel | Chief Development Officer |
Nov 26 '24 |
Option Exercise |
12.17 |
30,450 |
370,576 |
286,174 |
| Gupta Suneel | Chief Development Officer |
Nov 25 '24 |
Sale |
46.04 |
103,437 |
4,762,239 |
256,174 |
| Gupta Suneel | Chief Development Officer |
Nov 26 '24 |
Sale |
45.50 |
19,191 |
873,190 |
266,983 |
| PATEL DINESH V PH D | President and CEO |
Nov 25 '24 |
Option Exercise |
21.58 |
1,727 |
37,269 |
429,935 |
| PATEL DINESH V PH D | President and CEO |
Nov 25 '24 |
Sale |
46.96 |
78,520 |
3,687,299 |
435,208 |
| PATEL DINESH V PH D | President and CEO |
Nov 26 '24 |
Sale |
46.25 |
21,480 |
993,450 |
408,455 |
2.14%
5.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):